+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

ESR1-Mutated Metastatic Breast Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

ESR1-Mutated Metastatic Breast Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Breast Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Breast Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
From
HER2-Positive Early Breast Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

HER2-Positive Early Breast Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2025 - Product Thumbnail Image

Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Cathepsin S Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Cathepsin S Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
TYK2 Kinase Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

TYK2 Kinase Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Aurora-A Kinase Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Aurora-A Kinase Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Breast Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 100 Pages
  • Global
From
Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Ovarian Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Ovarian Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Aurora Kinase Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Aurora Kinase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Brain Metastasis From Breast Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Brain Metastasis From Breast Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Histone Deacetylase 6 - Pipeline Insight, 2025 - Product Thumbnail Image

Histone Deacetylase 6 - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Phosphatidylinositol 3-Kinase (PI3K) Inhibitors- Pipeline Insight, 2025 - Product Thumbnail Image

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more